Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non—insulin-dependent diabetes mellitus
- 31 July 1997
- journal article
- Published by Elsevier in Current Therapeutic Research
- Vol. 58 (7) , 403-416
- https://doi.org/10.1016/s0011-393x(97)80031-8
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patientsDiabetologia, 1996
- Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapyDiabetes Care, 1996
- Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agentsMetabolism, 1995
- Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in ratsDiabetes Research and Clinical Practice, 1995
- A Desktop Guide for the Management of Non‐insulin‐dependent Diabetes Mellitus (NIDDM): An UpdateDiabetic Medicine, 1994
- Effects of a New Oral Hypoglycaemic Agent (CS-045) on Metabolic Abnormalities and Insulin Resistance in Type 2 DiabetesDiabetic Medicine, 1994
- UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal SubjectsDiabetic Medicine, 1994
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in
C 57BL KsJ db db Metabolism, 1991 - A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitusDiabetes Research and Clinical Practice, 1991